Given Imaging IPO Proceeds Will Fund R&D To Expand Camera Pill Indications
This article was originally published in The Gray Sheet
Executive Summary
Given Imaging will use $15 mil. of a proposed $69.2 mil. initial public offering to fund further research and development of its wireless endoscopy diagnostic imaging system, according to an Aug. 22 prospectus filed with the Securities and Exchange Commission.
You may also be interested in...
Premier Purchasing Deal Almost A Given For M2A Camera Capsule Maker
Premier's two-year agreement with Given Imaging for the M2A wireless endoscopy diagnostic imaging capsule may lend support to the group purchasing organization's claim that is does not exclude smaller firms with emerging technologies
Premier Purchasing Deal Almost A Given For M2A Camera Capsule Maker
Premier's two-year agreement with Given Imaging for the M2A wireless endoscopy diagnostic imaging capsule may lend support to the group purchasing organization's claim that is does not exclude smaller firms with emerging technologies
Given camera pill
Given Imaging's swallowable capsule for visualizing the inside of the small intestine to detect polyps, cancer or causes of bleeding gains FDA market go-ahead Aug. 1 via agency's 510(k) de novo process. The diagnostic imaging system is intended for use in conjunction with other endoscopic or radiological examinations. The capsule incorporates a small camera, lights, image transmitter and eight-hour battery (1"The Gray Sheet" July 30, 2001, p. 14)